Management Team

Ms. Bourdow was appointed President, Chief Executive Officer, and member of the Trevena Board of Directors in October 2018, and as Chair of the Board in November 2023. She has served in various senior positions at Trevena since May 2015. She joined the Company as Chief Commercial Officer and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from 2013 until its acquisition by Merck & Co. (MRK), Inc. in January 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across multiple therapeutic areas. Ms. Bourdow previously served as a member of the board of directors for Sesen Bio from February 2020 until March 2023 and as a member of the board of directors for Nabriva Therapeutics plc. (NBRV) from June 2017 until July 2023.

Dr. Demitrack joined Trevena as Senior Vice President and Chief Medical Officer in May 2018. He is a board-certified psychiatrist with over thirty years of experience in both academic and industry settings in clinical neuroscience research. Prior to joining Trevena, Dr. Demitrack was Vice President of Clinical Strategy at Roivant Sciences from May 2017 to May 2018. From July 2003 to May 2017, Dr. Demitrack served as Vice President and Chief Medical Officer of Neuronetics, Inc., where he led the clinical development introducing the NeuroStar TMS Therapy System. Prior to this, Dr. Demitrack was Assistant Vice President for Global Medical Affairs in Neuroscience at Wyeth Pharmaceuticals where he was responsible for post-marketing clinical development of the Effexor XR brand. Dr. Demitrack also served as Medical Director of the New Antidepressant Team at Lilly Research Laboratories where he led the registration clinical development and the initial NDA submission program for the antidepressant, duloxetine (Cymbalta). Prior to his industry career, Dr. Demitrack was a faculty member of the Department of Psychiatry at the University of Michigan Medical School, where he directed the Michigan Eating Disorders Program and received federal grant funding in clinical research studying the neuroendocrine pathophysiology of eating disorders and the idiopathic conditions chronic fatigue syndrome and fibromyalgia. Dr. Demitrack received a BA in Physics from Columbia University and his MD from the Robert Wood Johnson Medical School in New Jersey. He completed his psychiatry residency training at the University of California-San Francisco and completed a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. Dr. Demitrack is a Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology. Dr. Demitrack has published over 100 articles, book chapters and reviews on the pathophysiology and treatment of mood disorders and related conditions.

Mr. Yoder was appointed Senior Vice President, Chief Business Officer & Head of Commercial Operations in November 2021, and was appointed Chief Compliance Officer in September 2024. He joined Trevena as Vice President of Commercial Operations and Sales in June 2018 and was promoted to Senior Vice President and Chief Commercial Officer in December 2018. Prior to this, he served as Senior Vice President and Head of Global Commercial Operations, Alliance Management and IT at Orexigen Therapeutics, a biopharmaceutical company, from March 2015 through June 2018. While at Orexigen, Mr. Yoder built the commercial infrastructure with a focus on innovative, efficient, and effective business process and architecture. Additionally, he led external business development efforts that delivered 11 partnership deals spanning 67 countries. Prior to joining Orexigen, Mr. Yoder spent 28 years at Merck, where he held various roles of increasing responsibility across global business operations and commercial functions. In several of these roles, he was responsible for oversight and execution of large-scale initiatives including integration following acquisitions and led a range of organizational design and corporate change initiatives. Mr. Yoder received his Bachelor of Science degree in biology from Dickinson College and earned his Master of Business Administration from Emory University.